Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of CHF10136 in Healthy Subjects and Asthmatic Subjects
NCT07851623Phase 1Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing CHF10136 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
CHF10136
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07851623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07851623.